The estimated Net Worth of K Gary Barnette is at least $1.65 Milione dollars as of 24 May 2024. K Barnette owns over 5,000 units of Veru Inc stock worth over $4,350 and over the last 19 years he sold VERU stock worth over $1,065,000. In addition, he makes $577,156 as Chief Scientific Officer at Veru Inc.
K has made over 3 trades of the Veru Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of VERU stock worth $6,700 on 24 May 2024.
The largest trade he's ever made was selling 100,000 units of Veru Inc stock on 16 December 2020 worth over $1,065,000. On average, K trades about 12,813 units every 124 days since 2006. As of 24 May 2024 he still owns at least 5,000 units of Veru Inc stock.
You can see the complete history of K Barnette stock trades at the bottom of the page.
Dr. K. Gary Barnette Ph.D. serves as Chief Scientific Officer of the Company. Dr. Barnette served as Senior Vice President of Scientific and Regulatory Affairs of Camargo Pharmaceutical Services (“Camargo”), a provider of drug development services specializing in the 505(b)(2) approval pathway, from October 2016 to September 2018, as Vice President of Scientific and Regulatory Affairs of Camargo from January 2016 to October 2016, and as Vice President of Drug Development of Camargo from May 2012 to January 2016. Dr. Barnette was also the co-founder of GTx, Inc., a men’s health and oncology public company, where he served in various roles from 2001 to 2012. From 1998 to 2001, Dr. Barnette worked for Solvay Pharmaceuticals, Inc., eventually serving as Director of Regulatory Affairs. From 1995 until 1998, Dr. Barnette served as Clinical Pharmacology and Biopharmaceutics Reviewer for the U.S. Food and Drug Administration. Dr. Barnette earned his Doctor of Philosophy, Basic Pharmaceutical Sciences from West Virginia University in 1995 and his Bachelor of Science from Salem College in 1989.
As the Chief Scientific Officer of Veru Inc, the total compensation of K Barnette at Veru Inc is $577,156. There are 4 executives at Veru Inc getting paid more, with Dr. Mitchell S. Steiner F.A.C.S, F.A.C.S., M.D. having the highest compensation of $1,426,295.
K Barnette is 52, he's been the Chief Scientific Officer of Veru Inc since 2018. There are 12 older and 1 younger executives at Veru Inc. The oldest executive at Veru Inc is Mario Eisenberger, 70, who is the Independent Director.
K's mailing address filed with the SEC is 2916 NORTH MIAMI AVENUE, SUITE 1000, MIAMI, FL, 33127.
Over the last 7 years, insiders at Veru Inc have traded over $5,672,221 worth of Veru Inc stock and bought 673,267 units worth $1,199,518 . The most active insiders traders include Mitchell Shuster Steiner, Harry Fisch e K Gary Barnette. On average, Veru Inc executives and independent directors trade stock every 33 days with the average trade being worth of $22,682. The most recent stock trade was executed by Harry Fisch on 24 May 2024, trading 4,000 units of VERU stock currently worth $5,000.
the female health company/veru healthcare is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. to realize this goal, veru healthcare has three divisions: pharmaceutical and devices, consumer health products, and public sector. for men, product and product candidates are in the areas of benign prostatic hyperplasia, male infertility, amelioration of side effects of hormonal prostate cancer therapies, prostate cancer, gout, and sexual dysfunction. women’s health has product candidates for female sexual health and advanced breast and ovarian cancers and markets fc2, a disposable contraceptive device, to ob gyn physicians and is the only female condom approved by fda that offers dual protection against sexually transmitted infections, including hiv/aids and the zika virus, and unintended pregnancy. since the female health company began distributing fc2 in 2007, the product has been shipped to 144 countries
Veru Inc executives and other stock owners filed with the SEC include: